Organogenesis price to book ratio ORGO

Market value divided by the book value of the company's net assets, since 2017.

Today, Oct 23, 2026: 0.9×
10-year median: 5.6×
Against its 10-year history: 0th; percentile: 0 is its lowest day, 100 its highest
10-year range: 0.9× to 174×
Peer median: 1.6×

Organogenesis' price to book ratio is 0.9× as of Oct 23, 2026.

That is below its ten-year median of 5.6×, lower than on 100% of days in the last ten years.

Over that time it ranged from 0.9× in Oct 2026 to 174× in Jan 2019.

The median for 10 large drugmakers of a similar size is 1.6×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	0.9×	0.9×	2.3×
2025	2.6×	1.4×	3.0×
2024	1.5×	1.1×	2.0×
2023	2.0×	0.9×	2.2×
2022	1.4×	1.3×	5.7×
2021	6.3×	6.3×	29.2×
2020	12.4×	5.6×	39.1×
2019	36.5×	8.5×	174×
2018	11.8×	11.8×	82.9×
2017	76.9×	75.9×	77.7×

Against its peers

Companies in Drug Manufacturers - General nearest Organogenesis' size, closest first, today.

Company	Price to book ratio
ORGOOrganogenesis	0.9×
NATRNatures Sunshine Products	1.3×
LFVNLifevantage	2.2×
SPROSpero Therapeutics	1.5×
ATNMActinium Pharmaceuticals	1.6×
ARVNArvinas	0.8×
PBYIPuma Biotechnology	4.1×
IRWDIronwood Pharmaceuticals	n/m
ZVRAZevra Therapeutics	2.7×
CRMDCorMedix	1.3×
COLLCollegium Pharmaceutical	2.4×
Peer median	1.6×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Organogenesis

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.